SG11201912146RA - Treatment For Migraine - Google Patents

Treatment For Migraine

Info

Publication number
SG11201912146RA
SG11201912146RA SG11201912146RA SG11201912146RA SG11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA
Authority
SG
Singapore
Prior art keywords
migraine
treatment
Prior art date
Application number
SG11201912146RA
Other languages
English (en)
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG11201912146RA publication Critical patent/SG11201912146RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201912146RA 2017-06-14 2018-06-25 Treatment For Migraine SG11201912146RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (1)

Publication Number Publication Date
SG11201912146RA true SG11201912146RA (en) 2020-01-30

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912146RA SG11201912146RA (en) 2017-06-14 2018-06-25 Treatment For Migraine

Country Status (25)

Country Link
US (1) US11471434B2 (pl)
EP (1) EP3638370B1 (pl)
JP (1) JP7130739B2 (pl)
KR (1) KR102594130B1 (pl)
CN (1) CN111093772B (pl)
AU (1) AU2018284330B2 (pl)
BR (1) BR112019026660A2 (pl)
CA (1) CA3067321A1 (pl)
CY (1) CY1123860T1 (pl)
DK (1) DK3638370T3 (pl)
ES (1) ES2847169T3 (pl)
GB (1) GB201709459D0 (pl)
HR (1) HRP20210108T1 (pl)
HU (1) HUE053089T2 (pl)
IL (1) IL271211B2 (pl)
LT (1) LT3638370T (pl)
MA (1) MA49396B1 (pl)
MD (1) MD3638370T2 (pl)
MX (1) MX2019014784A (pl)
PL (1) PL3638370T3 (pl)
PT (1) PT3638370T (pl)
RS (1) RS61481B1 (pl)
SG (1) SG11201912146RA (pl)
SI (1) SI3638370T1 (pl)
WO (1) WO2018229738A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂
CN113348018A (zh) * 2018-12-06 2021-09-03 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
DK1867644T3 (da) * 2003-07-24 2009-09-21 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
WO2005030753A2 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
NZ548169A (en) * 2003-12-30 2009-04-30 Euro Celtique Sa Piperazines useful for treating pain
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
EP2585446A4 (en) * 2010-06-22 2013-12-25 Shionogi & Co COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE
KR20240068752A (ko) 2010-06-25 2024-05-17 샤이어 휴먼 지네틱 테라피즈 인크. 치료제들의 cns 전달
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
IL310508A (en) 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
SI3416631T1 (sl) 2016-08-11 2019-09-30 Intrabio Ltd Terapevtska sredstva za nevrodegenerativne bolezni
SI3482754T1 (sl) 2016-08-11 2021-04-30 Intrabio Ltd Farmacevtski sestavki in uporabe usmerjene v motnje lizosomalnega shranjevanja
DK3600276T3 (da) 2017-03-28 2023-07-10 Intrabio Ltd Betahistin, eller et farmaceutisk acceptabelt salt deraf og en monoaminoxidase-inhibitor til anvendlese til behandling eller forebyggelse af et eller flere symptomer på svimmelhed hos et individ
WO2019079536A1 (en) 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
MX2020003427A (es) 2017-10-18 2020-09-14 Intrabio Ltd Agentes terapeuticos para enfermedades neurodegenerativas.
CN111712239A (zh) 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂
CN113348018A (zh) 2018-12-06 2021-09-03 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20220362189A1 (en) 2019-06-28 2022-11-17 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
PL3638370T3 (pl) 2021-05-17
MX2019014784A (es) 2021-11-16
CN111093772A (zh) 2020-05-01
SI3638370T1 (sl) 2021-04-30
IL271211B1 (en) 2023-09-01
RU2020100475A3 (pl) 2021-10-22
CA3067321A1 (en) 2018-12-20
JP2020526575A (ja) 2020-08-31
RU2020100475A (ru) 2021-07-14
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
ES2847169T3 (es) 2021-08-02
WO2018229738A1 (en) 2018-12-20
MD3638370T2 (ro) 2021-04-30
GB201709459D0 (en) 2017-07-26
IL271211B2 (en) 2024-01-01
US20200253905A1 (en) 2020-08-13
JP7130739B2 (ja) 2022-09-05
IL271211A (en) 2020-01-30
HRP20210108T1 (hr) 2021-03-19
DK3638370T3 (da) 2021-01-25
BR112019026660A2 (pt) 2020-07-14
EP3638370B1 (en) 2020-11-11
AU2018284330B2 (en) 2024-03-14
RS61481B1 (sr) 2021-03-31
MA49396B1 (fr) 2021-03-31
KR20210013518A (ko) 2021-02-04
MA49396A (fr) 2020-04-22
CN111093772B (zh) 2023-11-03
US11471434B2 (en) 2022-10-18
CY1123860T1 (el) 2022-05-27
PT3638370T (pt) 2021-01-26
HUE053089T2 (hu) 2021-06-28
AU2018284330A1 (en) 2020-01-02
LT3638370T (lt) 2021-03-25

Similar Documents

Publication Publication Date Title
IL265343A (en) Treatment of persistent migraine
IL291153A (en) Methods for treating or preventing migraine headaches
IL269371A (en) Treatment methods
GB201608885D0 (en) Treatment
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
EP3507838C0 (fr) Dispositif de traitement de pièces
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
IL271211A (en) Migraine treatment
IL270867A (en) Treatment method
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
SG10201913377VA (en) Treatment apparatus
GB201718985D0 (en) Treatment
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201617380D0 (en) Treatment for Osteoarthritis